Cidara Therapeutics, Inc. (CDTX)

Cidara Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	168.15	189.83	35.78	32.73	59.68	35.91
Cash & Short-Term Investments	168.15	189.83	35.78	32.73	59.68	35.91
Cash Growth	479.47%	430.56%	9.31%	-45.16%	66.18%	-28.56%
Accounts Receivable	1.69	1.69	14.08	5.72	5.36	11.18
Receivables	1.69	1.69	14.08	5.72	5.36	11.18
Prepaid Expenses	12.67	12.87	1.71	5.58	4.07	3.07
Restricted Cash	6.34	6.35	-	-	2.59	7.04
Other Current Assets	-	-	9.29	1.07	-	-
Total Current Assets	188.85	210.74	60.86	45.09	71.7	57.19
Property, Plant & Equipment	2.78	3.96	5.13	1.32	2.54	1.21
Other Long-Term Assets	0.1	0.1	1.05	1.07	1.08	2.02
Total Assets	191.73	214.8	67.03	47.49	75.33	60.42
Accounts Payable	4.9	3.61	3.77	1.45	1.3	4.57
Accrued Expenses	42.48	44.3	37.25	24.13	15.06	12.17
Current Portion of Long-Term Debt	-	-	-	-	2.59	7.02
Current Portion of Leases	1.44	1.64	1.3	1.21	1.15	0.94
Current Unearned Revenue	-	-	0.43	1	13.92	13.87
Other Current Liabilities	-	-	24.67	13.61	-	-
Total Current Liabilities	48.81	49.55	67.42	41.4	34.02	38.56
Long-Term Leases	1.24	1.93	3.58	-	1.32	-
Long-Term Unearned Revenue	-	-	-	-	18.41	11.15
Other Long-Term Liabilities	-	-	4.25	20.53	-	-
Total Liabilities	50.05	51.49	75.24	61.93	53.75	49.71
Common Stock	0	0	0	0	0.01	0
Additional Paid-In Capital	776.42	774.57	433.22	404.06	398.73	345.41
Retained Earnings	-634.74	-611.26	-441.43	-418.5	-377.17	-334.7
Total Common Equity	141.68	163.31	-8.21	-14.44	21.57	10.72
Shareholders' Equity	141.68	163.31	-8.21	-14.44	21.57	10.72
Total Liabilities & Equity	191.73	214.8	67.03	47.49	75.33	60.42
Total Debt	2.67	3.58	4.88	1.21	5.06	7.96
Net Cash (Debt)	165.48	186.25	30.9	31.52	54.62	27.95
Net Cash Growth	578.99%	502.73%	-1.96%	-42.29%	95.42%	-27.48%
Net Cash Per Share	18.89	29.33	7.07	9.02	20.83	13.45
Filing Date Shares Outstanding	12.97	10.95	10.95	4.45	3.41	2.4
Total Common Shares Outstanding	12.21	10.95	4.53	3.62	3.39	2.24
Working Capital	140.04	161.18	-6.56	3.69	37.68	18.63
Book Value Per Share	11.60	14.92	-1.81	-3.98	6.36	4.78
Tangible Book Value	141.68	163.31	-8.21	-14.44	21.57	10.72
Tangible Book Value Per Share	11.60	14.92	-1.81	-3.98	6.36	4.78
Machinery	-	3.44	3.32	2.96	3.06	2.97
Leasehold Improvements	-	0.43	0.43	0.43	0.43	0.43

Updated Mar 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q